史琛，华中科技大学附属协和医院 药学部 副主任
医学博士、主任药师、博士生导师
主要从事
药物递送及临床转化，抗肿瘤药理，临床药学
主要课题成果论著
主持国家自然科学基金面上项目3项及青年基金1项、湖北省自然科学基金面上2项、其他国家及省部级项目14项，参与国家、省及市级课题15余项，获得湖北省科技进步二等奖、中国药学会-医院药学创新奖等；以通讯作者/一作在STTT、eClinicalMedicine、APSB、JCR、CEJ、Pharmacol Ther、Journal of Nanobiotechnology、Carbohydrate Polymers等国际权威期刊发表学术论文70余篇，其中SCI收录40余篇；参编、参译论著7部,获批实用新型专利1项，受理发明专利3项。
科研活动
德国Saarland-University生物药学系
德国Philipps-University Marburg生物药学系
学术任职
中国药学会医院药学专业委员会 委员
中国医院协会药事管理专业委员会委员
中华医学会细菌感染与耐药防治分会（BISC）青年委员
中国药师协会药品临床评价工作委员会 委员
中国抗癌协会个案管理专委会常委 中国抗癌协会肿瘤临床药学专业委员会委员
中国药理学会药源性疾病专业委员会医院新药风险监测与管理分委会 副主任委员
中国抗癌协会肿瘤营养专业委员会肿瘤营养药学专家协作组 副组长
中国初级卫生保健基金会药学专业委员会 常务委员
湖北省药学会 理事
湖北省药学会医院药学专业委员会 常务委员
《中国医院药学杂志》编委、《肿瘤药学杂志》编委、 《医药导报》编委、《中国药房》编委、《J Microencapsul》编委
科研项目
国家重点研发计划“生物与信息融合（BT与IT融合）”重点专项（主持，在研），2023YFF1205004，抗癌联合用药云服务平台建设及其临床应用研究
国家自然科学基金面上项目（主持，在研），V-ATP酶介导巨噬细胞溶酶体酸化在MMAE类ADC药物诱发周围神经病变中的作用机制研究
湖北省卫健委（主持，在研），湖北省第二届医学青年拔尖人才
中国高校产学研创新基金资助高校科技/科研处（主持，在研），益生菌对口服阿片类药物的中重度癌痛患者肠道菌群肠道通透性和炎症因子的影响:一项开放标签、单臂、探索性临床研究
国家自然科学基金面上项目（主持，在研）Treg-Exo通过“CD39-CD73-腺苷轴”介导巨噬细胞选择性极化以促骨折愈合的作用及机制研究
国家自然科学基金面上项目（主持，在研）高仿生纳米系统靶向清除CAF及衰老CAF改善乳腺癌放疗抵抗的作用及机制研究
中华临床药学专项基金项目（主持，在研）肿瘤免疫营养治疗与免疫检查点抑制剂疗法临床疗效及不良反应的关联研究
湖北省自然科学基金面上项目（主持）远程磁控释药纳米粒靶向阻断TASK-3通道治疗三阴乳腺癌的实验研究
国家自然科学基金青年项目（主持）基于“二次破坏”效应构建具磁-药协同作用的纳米载体及其抗三阴乳腺癌的研究
湖北省卫生健康委青年人才项目（主持）应用益生菌改善中重度癌痛患者阿片耐受的临床研究
湖北省卫健委中医药科研项目面上项目（主持）粉防己碱协同FR-PLGA MNPs调控TASK-3通道抑制三阴乳腺癌细胞增殖的实验研究
吴阶平医学基金会（主持）肠内营养对中国肿瘤患者（肺癌、乳腺癌）内科治疗近期及生存期结局的影响
吴阶平医学基金会（主持）中国黑色素瘤的治疗模式、疗效及预后因素研究
吴阶平医学基金会 临床科研专项资助基金项目（主持）贝伐珠单抗注射液上市后安全性再评价和经济学评价
“白求恩·求索-药学科研能力建设”（主持）替雷利珠单抗注射液上市后安全性再评价和经济学评价——基于真实世界数据项目
中国药学会（主持）基于移动“癌痛药物治疗管理（MTM）”平台干预改善哀痛患者蔗农疗效的随机对照研究
中华国际医学交流基金会中青年医学研究专项基金项目（主持）益生菌通过调节肠道菌群改善癌痛患者阿片耐受的临床研究
吴阶平医学基金会 临床科研专项资助基金项目（主持）信迪利单抗注射液上市后安全性再评价和经济学评价——基于真实世界数据
湖北省重点研发计划项目（第一参与人）基于多组学的器官移植免疫抑制精准用药技术研发及应用
国家自然科学基金面上项目（第一参与人）基于间充质干细胞外泌体实现骨质疏松症的骨靶向"精准"治疗
国家重点研发计划-公共安全风险防控与应急技术装备（项目/课题骨干）法匹拉韦与磷酸氯喹组合的临床研究
论文代表作
1. Jian C #, Wu T #, Wang L, Fu Z, Zhang Q,Shi C*. Biomimetic nanoplatform for dual-targeted clearance of activated and senescent cancer-associated fibroblasts to improve radiation resistance in breast cancer. Small. 2024; 12: e2309279.
2. Wu T #, Wang L #, Jian C, Gao C, Liu Y, Fu Z,Shi C*. Regulatory T cell-derived exosome mediated macrophages polarization for osteogenic differentiation in fracture repair. Journal of Controlled Release. 2024; 369: 266-282.
3. Wu T #, Wang L #, Jian C, Zhang Z, Zeng R, Mi B, Liu G, Zhang Y,Shi C*. A distinct "repair" role of regulatory T cells in fracture healing. Front Med-PRC. 2024; 18(3):516-537.
4.Shi C#, Wang C#, Fu Z, Liu J, Zhou Y, Cheng B, Zhang C, Li S, Zhang Y. Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway, Pharmacological Research. 2024, 201: 107088.
5. Wu T #, Wang L #, Gao C, Jian C, Liu Y, Fu Z,Shi C*. Treg-Derived Extracellular Vesicles: Roles in Diseases and Theranostics. Mol Pharm. 2024; 21(6):2659-2672.
6. Xu C, Zeng F, Huang Y, Xu Q, Yang Y, Gong W,Shi C*, Zhang Y. Clinical efficacy of ceftazidime/avibactam combination therapy for severe hospital-acquired pulmonary infections caused by carbapenem-resistant and difficult-to-treat Pseudomonas aeruginosa. Int J Antimicrob Agents. 2024; 63(1):107021.
7. Chen W, Xie K, Gao C, Zhang C, Fu Z*,Shi C*. Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.Gynecol Oncol. 2024; 182:108-114.
8. Liu J, Luo J, Chen X, Xie J, Wang C, Wang H, Yuan Q, Li S, Zhang Y, Hu J,Shi C*. Opioid Nonadherence Risk Prediction of Patients with Cancer-Related Pain Based on Five Machine Learning Algorithms.Pain Res Manag. 2024:7347876.
9. Shi C#, Jian C, Wang L, Gao C, Yang T, Fu Z, Wu T. Dendritic cell hybrid nanovaccine for mild heat inspired cancer immunotherapy. Journal of Nanobiotechnology. 2023, 21(1): 347.
10.Shi C#, Zhang C, Fu Z, Liu J, Zhou Y, Cheng B, Wang C, Li S, Zhang Y. Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations. Acta Pharm Sin B. 2023; 13: 2613-27.
11. Fu Z, Liu J, Li S,Shi C*, Zhang Y. Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. EClinicalMedicine. 2023; 55: 101795.
12. Fu Z, Gao C, Wu T, Wang L, Li S, Zhang Y,Shi C*. Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience.2023, 26(10): 107778.
13. Fu Z, Li S, Han S,Shi C*, Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. Signal Transduct Target Ther. 2022; 7: 93.
14.Shi C#, Wu T, He Y, Zhang Y, Fu D. Recent advances in bone-targeted therapy. Pharmacol Ther. 2020; 207: 107473.
15. Gao X, Hua X, Wang X, Xu W, Zhang Y,Shi C*, Gu M. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022; 13: 935823.
16. Fu Z, Li S, Liu J, Zhang C, Jian C, Wang L, Zhang Y,Shi C*. Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer. Front Pharmacol. 2022; 13: 847906.
17.Shi C#, Liu J, Hu J, Chen X, Xie J, Luo J, Wang C, Wang H, Yuan Q, Zhu H, Gong W, Li S, Zhou H, Wang L, Wang H, Zhang Y. Genetic and Clinical Factors Associated with Opioid Response in Chinese Han Patients with Cancer Pain: An Exploratory Cross-Sectional Study. Pain Ther. 2022; 11: 269-88.
18. Wang H, Luo J, Chen X, Hu H, Li S, Zhang Y,Shi C*. Clinical Observation of the Effects of Oral Opioid on Inflammatory Cytokines and Gut Microbiota in Patients with Moderate to Severe Cancer Pain: A Retrospective Cohort Study. Pain Ther. 2022; 11: 667-81.
19. Wang X, Gu M, Gao X, Xiong X, Wang N, Li Q, Ge M, Luo M, Zhang Y, Hua X,Shi C*. Application of information-intelligence technologies in pharmacy intravenous admixture services in a Chinese third-class a hospital. BMC Health Serv Res. 2022; 22: 1238.
20. Wang Z, Min X, Hu Z, Sullivan MA, Tang Y, Wang L, Gilbert RG,Shi C*, Deng B. The fragility of liver glycogen from humans with type 2 diabetes: A pilot study. Int J Biol Macromol. 2022; 221: 83-90.
21. Xie J, Zhang C, Li S, Dai R, Deng B, Xu Q, Wang J,Shi C*, Zhang Y. Knowledge, attitudes, and practices toward cancer pain management amongst healthcare workers (physicians, pharmacists, and nurses): a cross-sectional study from first-tier cities in China. Support Care Cancer. 2022; 30: 7261-9.
22. Fu Z, Wang L, Li S, Chen F, Au-Yeung KK,Shi C*. MicroRNA as an Important Target for Anticancer Drug Development. Front Pharmacol. 2021; 12: 736323.
23. Gong Y, Luo L, Wang L, Chen J, Chen F, Ma Y, Xu Z, Sun Y, Luo L,Shi C*, Li X. Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. J Clin Pharm Ther. 2021; 46: 1557-63.
24. Gu M, Hua XL, Li SJ, Luo J, Liu JM, Zhang Y,Shi C*. Application of Quality Control Circle Activity in Improving Effectiveness of Drug Intervention in Lung Cancer Patients with Moderate to Severe Pain. Curr Med Sci. 2021; 41: 996-1003.
25. Guo Y, Liu Y,Shi C#, Wu T, Cui Y, Wang S, Liu P, Feng X, He Y, Fu D. Remote-controllable bone-targeted delivery of estradiol for the treatment of ovariectomy-induced osteoporosis in rats. J Nanobiotechnology. 2021; 19: 248.
26. Liu J, Zhang M, Luo J, Xie J, Chen X, Wang H, Li S, Yang S, Peng C, Yang L, Deng B, Zhang Y, Wang C, Hu J,Shi C*. Practice, Knowledge, and Attitude of Health Care Providers regarding Cancer Pain Management: A National Survey. Pain Res Manag. 2021; 2021: 1247202.
27.Shi C#, Tingting W, Li JP, Sullivan MA, Wang C, Wang H, Deng B, Zhang Y. Comprehensive Landscape of Heparin Therapy for COVID-19. Carbohydr Polym. 2021; 254: 117232.
28.Shi C#, Wang X, Diao C, Zhu H, Yuan Q, Liu J, Li S, Gu M, Zhang Y. Toxicities and Associated Factors in Patients Receiving Temozolomide-Containing Regimens: A 12-Year Analysis of Hospital Data. Drug Des Devel Ther. 2021; 15: 2151-9.
29. Xie J, Zhang C, Li S, Dai R, Sullivan MA, Deng B, Xu Q, Wang J,Shi C*, Zhang Y. Efficacy and Safety of Thalidomide As a Pre-Medication of Chemotherapy-Induced Nausea and Vomiting (CINV) Following Highly Emetogenic Chemotherapy (HEC): A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11: 818839.
30. Zhang Q, Liu X, Sullivan MA,Shi C*, Deng B. Protective Effect of Yi Shen Pai Du Formula against Diabetic Kidney Injury via Inhibition of Oxidative Stress, Inflammation, and Epithelial-to-Mesenchymal Transition in db/db Mice. Oxid Med Cell Longev. 2021; 2021: 7958021.
31. Zhang Y, Li Y, Zhao J, Wang C, Deng B, Zhang Q,Shi C*. Protective Effects and Mechanisms of Polyethylene Glycol Loxenatide Against Hyperglycemia and Liver Injury in db/db diabetic Mice. Front Pharmacol. 2021; 12: 781856.
32. He Q, Hu H, Zhang Q, Wu T, Zhang Y, Li K,Shi C*. Ultra-dispersed biomimetic nanoplatform fabricated by controlled etching agglomerated MnO2 for enhanced photodynamic therapy and immune activation. Chemical Engineering Journal. 2020; 397.
33. Hua X, Gu M, Zeng F, Hu H, Zhou T, Zhang Y,Shi C*. Pharmacy administration and pharmaceutical care practice in a module hospital during the COVID-19 epidemic. J Am Pharm Assoc (2003). 2020; 60: 431-8 e1.
34. Liu J, Wang C, Chen X, Luo J, Xie J, Li S, Hu J,Shi C*. Evaluation of pharmacist interventions as part of a multidisciplinary cancer pain management team in a Chinese academic medical center. J Am Pharm Assoc (2003). 2020; 60: 76-80.
35.Shi C#, Wang C, Wang H, Yang C, Cai F, Zeng F, Cheng F, Liu Y, Zhou T, Deng B, Vlodavsky I, Li JP, Zhang Y. The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. Clin Transl Sci. 2020; 13: 1087-95.
36. Wu T, Zhang Q, Hu H, Yang F, Li K, Zhang Y,Shi C*. Enhancing cellular morphological changes and ablation of cancer cells via the interaction of drug co-loaded magnetic nanosystems in weak rotating magnetic fields. RSC Adv. 2020; 10: 14471-81.
37. Zhang Y, Hu H, Tang W, Zhang Q, Li M, Jin H, Huang Z, Cui Z, Xu J, Wang K,Shi C*. A multifunctional magnetic nanosystem based on "two strikes" effect for synergistic anticancer therapy in triple-negative breast cancer. J Control Release. 2020; 322: 401-15.
38. Zhao Y, Chen Z, Huang P, Zheng SW, Xu QL,Shi C*. Analysis of Ornidazole Injection in Clinical Use at Post-marketing Stage by Centralized Hospital Monitoring System. Curr Med Sci. 2019; 39: 836-42.
39. Wang K, Hu H, Zhang Q, Zhang Y,Shi C*. Synthesis, purification, and anticancer effect of magnetic Fe3O4-loaded poly (lactic-co-glycolic) nanoparticles of the natural drug tetrandrine. Journal of Microencapsulation. 2019; 36(4):356-370
40. Hu H, Zhang Y, Ji W, Mei H, Wu T, He Z, Wang K,Shi C*. Hyaluronic acid-coated and Olaparib-loaded PEI -PLGA nanoparticles for the targeted therapy of triple negative breast cancer. Journal of Microencapsulation. 2022; 39(1):25-36
41. Drug-loaded poly(D,L -lactide-co-glycolide) microspheres as treatment for allergic contact dermatitis in mice model. Journal of Bioactive and Compatible Polymers (2017)
42. Clinical application analysis of andrographolide total ester sulfonate injection, a traditional Chinese medicine licensed in China. Journal of Huazhong University of Science and Technology (2017)
43.Inhibition of the cancer-associated TASK 3 channels by magnetically induced thermal release of Tetrandrine from a polymeric drug carrier, Journal of Controlled Release (2016)
44. A novel study on the mechanis5ms of drug release in PLGA-mPEG microspheres with fluorescent drug,J Biomater Sci Polym Ed (2016)
45.The effects of mPEG proportion and LA/GA ratio on degradation and drug release behaviors of PLGA-mPEG microparticles,Pharmazie (2016)
46.Multilayer Coating of Tetrandrine-loaded PLGA Nanoparticles: Effect of Surface Charges on Cellular Uptake Rate and Drug Release Profile,J Huazhong Univ Sci Technol［Med Sci］(2016)
47.Improved delivery of the natural anticancer drug tetrandrine, International Journal of Pharmaceutics；0378-5173；2015
48.ε-Polylysine and next-generation dendrigraft poly-L-lysine: chemistry, activity, and applications in biopharmaceuticals,Journal Journal of Biomaterials Science, Polymer Edition；0920-5063；2015
联系方式：027-85726192 E-mails: whxhchen@163.com
通讯地址：武汉市解放大道1277号 华中科技大学附属协和医院药学部430022
